Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4MSLY)

Drug Name
ZN-c3 Drug Info
Indication
Disease Entry ICD 11 Status REF
Uterine serous carcinoma 2C72.1 Phase 2 [1]
Cross-matching ID
PubChem CID
139467635
TTD Drug ID
DM4MSLY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Wee1-like protein kinase (WEE1) DTT WEE1 6.931 6.197 5.869 6.38
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Uterine serous carcinoma
ICD Disease Classification 2C72.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Wee1-like protein kinase (WEE1) DTT WEE1 7.06E-07 1.06 4.21
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04814108) A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.